Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors

Trial Details

NCT ID

NCT05997056

Phase

PHASE2

Sponsor

Aadi Bioscience, Inc.

Status

RECRUITING

Cancer Type

Pancreatic Neuroendocrine Pancreatic Cancer

Interventions

• nab-sirolimus

Locations (sample)

• Newport Beach, California, United States|33.61891,-117.92895
• Denver, Colorado, United States|39.73915,-104.9847
• Dallas, Texas, United States|32.78306,-96.80667
• Milwaukee, Wisconsin, United States|43.0389,-87.90647

Key Eligibility Criteria

• Patients with functional or non-functional, well-differentiated, locally advanced unresectable or metastatic NETs of the GI tract, lung, or pancrea…
• Patients with functional NETs may enroll if:
• the patient has been on a stable dose of an somatostatin analogs for ≥12 weeks and
• the patient has experienced disease progression while on stable somatostatin analogs dose

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.